Greetings
The company was established in April 2018 for two objectives. The first is to commercialize a rapid development system for high-affinity, high stable, and high productive antibodies, which was established by Akikazu Murakami CEO, also a faculty member of the Graduate School of Medicine, The University of Ryukyus. The second is to bank the natural bacteriophages latent in Okinawa, and to develop pharmaceuticals and quasi-drugs.
1. Providing high-affinity, high-stable and high-productive VHH antibodies by a rapid development method
(VHH antibody service).
To develop pharmaceuticals and test drugs, not only the production of high-performance antibodies, but also a large amount of antibody production system is required. The development of antibodies involves many steps and high costs, such as immunization of animals and establishment of antibody-producing hybridoma cell lines, which can hinder R & D.
We have the technology to rapidly develop camelid VHH antibodies by using an antibody library method (phage display method) using bacteriophage without using animals. This technology is highly stable, inexpensive, and the obtained VHH antibodies can be mass-produced compared to general antibodies.
For details, see the “VHH antibody service”.
2. Isolation of bacteriophage and development of pharmaceuticals (Natural phage service).
Bacteriophages infect bacteria and many of them have a lytic (bactericidal) effect, so they have long been used to treat infections and have been studied for over 100 years.
However, the appearance of antibiotics has made phage therapy a forgotten method in Western countries. However, in recent years, the problem of drug-resistant bacteria has become serious, and the use of bacteriophage (phage therapy) has been reviewed worldwide as one of effective measures against it, and approval of phage preparations has been rapidly promoted mainly in Europe and the United States.
Our company has the technical know-how to efficiently collect and isolate bacteriophages that have a high bactericidal ability for a wide range of bacteria from nature. We are developing phage preparations that can kill multidrug-resistant bacteria.